Mylan NV (MYL)

39.59
0.95 2.46
NASDAQ : Health Care
Prev Close 38.64
Open 38.93
Day Low/High 38.79 / 40.10
52 Wk Low/High 37.59 / 67.34
Volume 7.41M
Avg Volume 5.80M
Exchange NASDAQ
Shares Outstanding 535.95M
Market Cap 20.33B
EPS 1.80
P/E Ratio 37.56
Div & Yield N.A. (N.A)

Latest News

Stocks Lift Off on Boeing, Lockheed Martin Deals; Crude Settles at One-Month High

Stocks Lift Off on Boeing, Lockheed Martin Deals; Crude Settles at One-Month High

Donald Trump gives Wall Street a burst of relief on Monday after causing worry on markets for the previous two weeks.

Defense Stocks Lift Wall Street, Qualcomm and Apple Lead Tech Shares

Defense Stocks Lift Wall Street, Qualcomm and Apple Lead Tech Shares

Defense stocks lift Wall Street to begin the week after Donald Trump's first leg of a trip abroad results in billions of dollars' worth of deals.

Midday Report: Boeing Leads the Dow; JPMorgan Has Faith in Qualcomm

Midday Report: Boeing Leads the Dow; JPMorgan Has Faith in Qualcomm

Defense stocks lifted Wall Street to begin the week after Donald Trump's first leg of a trip abroad resulted in billions of dollars' worth of deals.

Mylan Stock Gains Following Barclays Upgrade

Mylan Stock Gains Following Barclays Upgrade

The firm upgraded Mylan to 'overweight' from 'equal weight.'

Here's What Carl Icahn Bought and Sold in the First Quarter

Here's What Carl Icahn Bought and Sold in the First Quarter

Carl Icahn exited his positions in Allergan and Nuance Communications during the first quarter of the year and acquired a stake in a Xerox spinoff after pressuring for a split.

Hikma Shares Plunge After It Says 'Low Likelihood' of 2017 Generic Advair Approval

Hikma Shares Plunge After It Says 'Low Likelihood' of 2017 Generic Advair Approval

Hikma shares plunged the most in nine months inLondon trading Thursday after the drugmaker said that approval of its generic Advair Diskus asthma treatment faces delays from the FDA.

Wall Street Dissects What Trump's Comey Firing Means for Agenda, Disney Drags on Dow

Wall Street Dissects What Trump's Comey Firing Means for Agenda, Disney Drags on Dow

Stocks trade mixed on Wednesday after Donald Trump's firing of FBI Director James Comey wraps the White House in another controversy.

Mylan Unhappy With FDA Standards for Asthma Drug

Mylan Unhappy With FDA Standards for Asthma Drug

Earlier this year the FDA sent Mylan a letter saying it would not approve its drug.

Stocks Fall as Trump's Comey Firing Distracts From Progress in Tax Cut Plan

Stocks Fall as Trump's Comey Firing Distracts From Progress in Tax Cut Plan

Stocks trade lower on Wednesday after Donald Trump's firing of FBI Director James Comey wraps the White House in another controversy.

Biotech Movers: Depomed Shares Tank After Losses Get Even Worse

Biotech Movers: Depomed Shares Tank After Losses Get Even Worse

Depomed unveiled steps the company is taking to shore itself up.

Hikma Shares Slide Amid Speculation of FDA Ruling on Generic Advair

Hikma Shares Slide Amid Speculation of FDA Ruling on Generic Advair

Hikma Pharmaceuticals fell sharply in London ahead of a crucial decision by the U.S. Food & Drug Administration on whether to approve its generic Advair asthma treatment.

Mylan Revenue Jumps 24%

Mylan Revenue Jumps 24%

Mylan CEO Heather Bresch says the first quarter marks "a great start."

Stock Futures Fall After Trump Axes FBI Director Comey

Stock Futures Fall After Trump Axes FBI Director Comey

Stock futures move lower on Wednesday after Donald Trump fires FBI Director James Comey in a move that shocked political pundits.

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

U.S. stock futures point lower Wednesday, suggesting Wall Street will follow European markets lower after Donald Trump fires James Comey as director of the FBI in a surprise move.

Mylan's Prospects Brighten as EpiPen Maker's Diversification Efforts Pay Off

Mylan's Prospects Brighten as EpiPen Maker's Diversification Efforts Pay Off

Mylan's moves away from the troubles of its EpiPen are yielding results, which should be reflected in first-quarter earnings.

Week Ahead: Department Stores Set to Report Earnings Amid Retail's 'Creeping Armageddon'

Week Ahead: Department Stores Set to Report Earnings Amid Retail's 'Creeping Armageddon'

We're rounding out the end of the earnings season and it's retail's turn to step up to the plate and show us what it's got.

Generics Drop Across Board as DOJ Inquiry Expands

Generics Drop Across Board as DOJ Inquiry Expands

The addition of Perrigo to the list of generics makers under investigation is more bad news for a sector already under pressure from low prices.

Perrigo Stock Sliding on DOJ Search

Perrigo Stock Sliding on DOJ Search

The investigation is in relation to drug pricing in the pharmaceutical industry.

Mylan Chairman Received Compensation Totaling Nearly $100 Million in 2016

Mylan Chairman Received Compensation Totaling Nearly $100 Million in 2016

Mylan was under scrutiny for drastically raising the price of its life-saving EpiPen allergic tratment.

Astrazeneca Shares Gain After FDA Approves 'Durvalumab' Bladder Cancer Treatment

Astrazeneca Shares Gain After FDA Approves 'Durvalumab' Bladder Cancer Treatment

AstraZeneca shares edged higher Tuesday after it passed another key milestone in its pivot toward an oncology focused portfolio.

Drug Maker Mylan Tries to Put Prices on Hold

Drug Maker Mylan Tries to Put Prices on Hold

It looks like the stock is trying to rebase again.

Mylan Nominates Sjoerd Vollebregt For Election To Board Of Directors

Mylan Nominates Sjoerd Vollebregt For Election To Board Of Directors

Directors Douglas Leech, Joseph Maroon and Rodney Piatt to Retire from Board

Glaxo Stock Slumps as Investors Eye Advair Generics

Glaxo Stock Slumps as Investors Eye Advair Generics

Mylan's setback may not be enough to prevent generic Advair reaching the market in 2017

Why Mylan, Perrigo and Endo Won't Be Playing Spoiler in Akorn-Fresenius Tie Up

Why Mylan, Perrigo and Endo Won't Be Playing Spoiler in Akorn-Fresenius Tie Up

Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion, or $34 per share.

K-Mart to Sell Cheaper EpiPen Alternative

K-Mart to Sell Cheaper EpiPen Alternative

K-Mart will charge cash paying customers $199 for a two-pack vs. Mylan's $643.